Advertisement

Topics

The Multiple Myeloma Research Consortium (MMRC) Company Profile

01:44 EDT 21st March 2019 | BioPortfolio

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.


News Articles [1192 Associated News Articles listed on BioPortfolio]

Unique Genetic Makeup of Myeloma Tumor Cells Profiled

Multiple myeloma is the second-most common type of blood cancer. Multiple myeloma occurs when plasma cells in the bone marrow,...

Current and Prospective Therapies Are Improving Outcomes in Relapsed Multiple Myeloma

During an OncLive Peer Exchange®, a panel of experts on multiple myeloma discussed new agents and combinations that are improving the care of patients with relapsed multiple myeloma and revie...

Multiple Myeloma continues to be characterised by its unmet needs

Despite the latest advances in the treatment of multiple myeloma (MM), unmet needs abound in this difficult-to-treat oncology indication, despite...Read More... The post Multiple Myeloma continues to ...

Results from the EMN-011 trial, combination therapy for multiple myeloma

Prof Pieter Sonneveld speaks to ecancer at ASH 2018 about a clinical trail from the European Myeloma Network for newly diagnosed multiple myeloma, transplant eligible patients. He outlines the study ...

The MMRF CoMMpass Study Drives New Discoveries in Multiple Myeloma

NORWALK, Conn., Dec. 1, 2018 /PRNewswire/ -- Today, the Multiple Myeloma Research Foundation (MMRF) announced new discoveries driven by its landmark CoMMpass StudySM into defining Read more...

MRD Status a Superior Predictor of PFS in Multiple Myeloma?

The study also looks at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients.

Expert Explains Latest Developments in Multiple Myeloma

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Advances offer Promise for Multiple Myeloma Patients

Dr. Bill Benisnger M.D. of Swedish Cancer Inst. discusses the growing number of treatment options for Multiple Myeloma

PubMed Articles [2482 Associated PubMed Articles listed on BioPortfolio]

Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis.

Multiple myeloma (MM) is a common malignancy belonging to the hematological system. The translocation t(4;14)(p16.3;q32.3) is a critical cytogenetic change of MM, which is presenting a poor prognosis....

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that co...

Severe Cytomegalovirus Enterocolitis Developing following Daratumumab Exposure in Three Patients with Multiple Myeloma.

Survival of multiple myeloma (MM) patients has improved with introduction of novel anti-myeloma agents. Myeloma has transformed into a chronic condition, accompanied with multiple relapses requiring s...

Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma.

To investigate the association between occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma (MM) in a large, consortium-based study.

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Genetic variants in genes acting during the maturation process of immature B-cell to differentiated plasma cell could influence the risk of developing multiple myeloma (MM). During B-cell maturation, ...

Clinical Trials [5421 Associated Clinical Trials listed on BioPortfolio]

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to ...

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

The purpose of this research study is to determine the safety of CCI-779 and bortezomib, and the highest dose of this drug that can be given to people safely. We will also be looking at h...

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

The goal of this research study is to learn about the pain and/or other symptoms that patients may experience during and after treatment for multiple myeloma (MM) and how these symptoms ma...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

Companies [2038 Associated Companies listed on BioPortfolio]

The Multiple Myeloma Research Consortium (MMRC)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, mo...

The Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myelo...

Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) is a 509(a) 3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myel...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

More Information about "The Multiple Myeloma Research Consortium (MMRC)" on BioPortfolio

We have published hundreds of The Multiple Myeloma Research Consortium (MMRC) news stories on BioPortfolio along with dozens of The Multiple Myeloma Research Consortium (MMRC) Clinical Trials and PubMed Articles about The Multiple Myeloma Research Consortium (MMRC) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Multiple Myeloma Research Consortium (MMRC) Companies in our database. You can also find out about relevant The Multiple Myeloma Research Consortium (MMRC) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record